RET/PTC1-Driven Neoplastic Transformation and Proinvasive Phenotype of Human Thyrocytes Involve Met Induction and β-Catenin Nuclear Translocation

作者: Giuliana Cassinelli , Enrica Favini , Debora Degl'Innocenti , Alessandro Salvi , Giuseppina De Petro

DOI: 10.1593/NEO.08916

关键词: CateninProto-Oncogene Proteins c-retGene silencingTyrosine kinaseBiologyProtein kinase BCancer researchNeoplastic transformationBeta-cateninPhenotype

摘要: Activation of the RET gene by chromosomal rearrangements generating RET/PTC oncogenes is a frequent, early, and causative event in papillary thyroid carcinoma (PTC). We have previously shown that, human primary thyrocytes, RET/PTC1 induces transcriptional program including MET proto-oncogene. In PTCs, β-catenin frequently mislocated to cytoplasm nucleus. investigated interplay between Ret/ptc1 signaling Met regulating proinvasive phenotype localization cellular models PTC. Here, we show that protein expressed constitutively active thyrocytes exogenously expressing as well mutant (Y451F) devoid main multidocking site. Both transformed PTC cell line TPC-1, Ret/ptc1-Y451-dependent cooperated promote phenotype. Accordingly, gene/functional silencing either or abrogated early branching morphogenesis TPC-1 cells. The same effect was obtained blocking common downstream effector Akt. Y451 required proliferation nuclear translocation β-catenin, suggesting these oncogene-driven effects are Met-independent. Pharmacologic inhibition tyrosine kinases multitarget small molecule RPI-1 blocked invasive ability dislocated from Altogether, results support cross talks with at levels promotes activity drive thyrocyte neoplastic transformation. Such molecular network, promoting disease initiation acquisition phenotype, highlights new options design therapeutic strategies for PTCs.

参考文章(53)
Luigi P. Ruco, Antonella Stoppacciaro, Francesca Ballarini, Maria Prat, Stefania Scarpino, Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis. The Journal of Pathology. ,vol. 194, pp. 4- 8 ,(2001) , 10.1002/PATH.847
M. G. Borrello, L. Alberti, A. Fischer, D. Degl'Innocenti, C. Ferrario, M. Gariboldi, F. Marchesi, P. Allavena, A. Greco, P. Collini, S. Pilotti, G. Cassinelli, P. Bressan, L. Fugazzola, A. Mantovani, M. A. Pierotti, Induction of a proinflammatory program in normal human thyrocytes by the RET/PTC1 oncogene Proceedings of the National Academy of Sciences of the United States of America. ,vol. 102, pp. 14825- 14830 ,(2005) , 10.1073/PNAS.0503039102
K. A. B. Knostman, S. M. Jhiang, C. C. Capen, Genetic Alterations in Thyroid Cancer: The Role of Mouse Models: Veterinary Pathology. ,vol. 44, pp. 1- 14 ,(2007) , 10.1354/VP.44-1-1
V Vasko, M Saji, E Hardy, M Kruhlak, A Larin, V Savchenko, M Miyakawa, O Isozaki, H Murakami, T Tsushima, KD Burman, C De Micco, MD Ringel, Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer Journal of Medical Genetics. ,vol. 41, pp. 161- 170 ,(2004) , 10.1136/JMG.2003.015339
Thomas J Giordano, Rork Kuick, Dafydd G Thomas, David E Misek, Michelle Vinco, Donita Sanders, Zhaowen Zhu, Raffaele Ciampi, Michael Roh, Kerby Shedden, Paul Gauger, Gerard Doherty, Norman W Thompson, Samir Hanash, Ronald J Koenig, Yuri E Nikiforov, Molecular classification of papillary thyroid carcinoma: distinct BRAF , RAS , and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis Oncogene. ,vol. 24, pp. 6646- 6656 ,(2005) , 10.1038/SJ.ONC.1208822
D Lantsov, S Meirmanov, M Nakashima, H Kondo, V Saenko, Y Naruke, H Namba, M Ito, A Abrosimov, E Lushnikov, I Sekine, Sh Yamashita, Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant β‐catenin expression Histopathology. ,vol. 47, pp. 248- 256 ,(2005) , 10.1111/J.1365-2559.2005.02218.X
G. Cuccuru, C. Lanzi, G. Cassinelli, G. Pratesi, M. Tortoreto, G. Petrangolini, E. Seregni, A. Martinetti, D. Laccabue, C. Zanchi, F. Zunino, Cellular Effects and Antitumor Activity of RET Inhibitor RPI-1 on MEN2A-Associated Medullary Thyroid Carcinoma Journal of the National Cancer Institute. ,vol. 96, pp. 1006- 1014 ,(2004) , 10.1093/JNCI/DJH184
Taranjit S. Gujral, Wendy van Veelen, Douglas S. Richardson, Shirley M. Myers, Jalna A. Meens, Dennis S. Acton, Mireia Duñach, Bruce E. Elliott, Jo W.M. Höppener, Lois M. Mulligan, A Novel RET Kinase–β-Catenin Signaling Pathway Contributes to Tumorigenesis in Thyroid Carcinoma Cancer Research. ,vol. 68, pp. 1338- 1346 ,(2008) , 10.1158/0008-5472.CAN-07-6052
M G Borrello, L Alberti, E Arighi, I Bongarzone, C Battistini, A Bardelli, B Pasini, C Piutti, M G Rizzetti, P Mondellini, M T Radice, M A Pierotti, The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma Molecular and Cellular Biology. ,vol. 16, pp. 2151- 2163 ,(1996) , 10.1128/MCB.16.5.2151